FDMT

4D Molecular Therapeutics Inc

CIK 0001650648
Employees 196
Phone 510 505 2680
Fiscal year end December
IPO Dec 11, 2020
Address 5858 Horton Street, EmeryVille, CA, United States, 94608
12.28
+0.33 (+2.76%)
USD · NASDAQ
52-week range
6.96
16.93
Trading at 53% of the 52-week range
Market Cap
678.40M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
7.38
Div. Yield
N/A
% Institutions
106.70%
% Insiders
2.72%

1 Year

+14.2%

3 Year

+6.8%

10 Year

-69.7%
Description

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Actions

Add an action for FDMT.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. John F. Milligan Ph.D. Executive Chairman 1961
Dr. David H. Kirn M.D. Co-Founder, President, CEO & Director 1962
Mr. Kristian Humer M.B.A. CFO and Principal Financial & Accounting Officer 1976
Dr. Fariborz Kamal Ph.D. Chief Technical Advisor 1963
Ms. Theresa Janke Co-Founder & Chief of Staff 1975
Julian Pei Head of Investor Relations & Corporate Finance NA
Dr. Katy Barglow Ph.D. Chief Technical Officer NA
Dr. Scott P. Bizily J.D., Ph.D. Chief Legal Officer & Corporate Secretary 1972
Dr. An Song Ph.D. Chief Translational Medicine Advisor NA
Dr. Noriyuki Kasahara M.D., Ph.D. Chief Scientific Advisor 1963

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Mar 20, 2026 Ashoo Gupta N/A Sale 390.00 $8.61 $3.36K SEC
Dec 20, 2025 Ashoo Gupta N/A Sale 389.00 $8.68 $3.38K SEC
Dec 16, 2025 Scott Bizily N/A Sale 1.64K $10.90 $17.82K SEC
Nov 17, 2025 Scott Bizily N/A Sale 1.64K $10.59 $17.31K SEC
Oct 24, 2025 Scott Bizily N/A Sale 2.68K $12.00 $32.14K SEC
Oct 16, 2025 Scott Bizily N/A Sale 1.64K $10.17 $16.63K SEC
Oct 09, 2025 Scott Bizily N/A Sale 2.41K $10.00 $24.08K SEC
Sep 23, 2025 Scott Bizily N/A Sale 2.41K $8.00 $19.26K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Woodline Partners LP 200.00K Jun 30, 2026 0.36% $0.01 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 1.59M 2.88% ▲ 0.00% Sep 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 1.23M 2.22% ▼ 0.80% Oct 29, 2026
3 iShares Russell 2000 ETF 1.15M 2.09% ▼ 0.41% Oct 29, 2026
4 Janus Henderson Hrzn Biotec E2 USD 904.51K 1.64% ▼ 8.11% Jun 30, 2026
5 Janus Henderson Global Life Sciences D 865.42K 1.57% ▲ 9.76% Aug 31, 2026
6 Janus Henderson Glb Life Scn I2 USD 837.86K 1.52% ▲ 5.96% Aug 31, 2026
7 Janus Global Life Science AUSD 793.17K 1.44% ▲ 1.30% Jun 30, 2026
8 T. Rowe Price Small-Cap Stock 545.41K 0.99% ▼ 40.52% Sep 30, 2026
9 Fidelity Small Cap Index 501.54K 0.91% ▲ 1.06% Jul 31, 2026
10 T. Rowe Price Small-Cap Value 431.35K 0.78% ▲ 0.00% Sep 30, 2026

Financial Highlights

▼
Market Cap: $678.40M
EBITDA: $-188.89M
Book Value: $7.38
Earnings/Share: $-2.63
Profit Margin: -194.74%
Operating Margin: -2,037.16%
ROA (TTM): -25.09%
ROE (TTM): -43.25%
Revenue (TTM): $92.01M
Revenue/Share (TTM): $1.42
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 25,106.70%

Valuation Metrics

Enterprise Value: $338.60M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 55.24M
Shares Float: 42.55M
% Insiders: 2.72%
% Institutions: 106.70%
Shares Short: 11.53M
Shares Short (Prior Month): 11.24M
Short Ratio: 10.77
Short % Float: 23.93%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$85.21M
Cost of Goods Sold
adjust
$-7.63M
Gross Profit
subtotal
$77.58M
SG&A
adjust
$-49.06M
R&D
adjust
$-195.70M
Operating Income
subtotal
$-159.55M
Other / Non-Operating Items
adjust
$19.44M
Net Income
subtotal
$-140.11M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about FDMT.US!